Finance·Aug 31, 2026
Samsung Biologics Plans $2.2 Billion Rights Offering to Fund Peptide Acquisition
South Korean contract manufacturer will issue 2.27 million new shares at discounted price as pharmaceutical industry consolidation accelerates
By Jun-ho Seo · 3 min ·


